Section Arrow
Quote
LIXT.NASDAQ
- Lixte Biotechnology Holdings
Quotes are at least 15-min delayed:2026/04/22 03:20 EDT
Regular Hours
Last
 3.48
+0.045 (+1.31%)
Day High 
3.48 
Prev. Close
3.435 
1-M High
3.65 
Volume 
12.41K 
Bid
--
Ask
--
Day Low
3.25 
Open
3.35 
1-M Low
2.5 
Market Cap 
39.91M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.09 
20-SMA 3.02 
50-SMA 2.96 
52-W High 6.26 
52-W Low 0.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.26/--
Enterprise Value
39.91M
Balance Sheet
Book Value Per Share
0.68
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
GERNGeron Corp1.5-0.06-3.85%-- 
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drugproduct pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.